{"id":"gb491-combined-with-letrozole","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Arthralgia"}]},"_chembl":{"chemblId":"CHEMBL1444","moleculeType":"Small molecule","molecularWeight":"285.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GB491 is an investigational agent being studied in combination with Letrozole, an aromatase inhibitor used in estrogen receptor-positive breast cancer. The combination approach targets both cell-cycle progression and hormonal signaling to enhance anti-tumor efficacy. This dual mechanism aims to overcome resistance and improve outcomes in hormone-sensitive breast malignancies.","oneSentence":"GB491 combined with Letrozole works by inhibiting a molecular target (likely CDK4/6 or similar cell-cycle regulator) to arrest tumor cell proliferation, while Letrozole blocks aromatase to reduce estrogen production in hormone receptor-positive breast cancer.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:13:41.519Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative breast cancer (presumed, based on Letrozole pairing)"}]},"trialDetails":[{"nctId":"NCT05851014","phase":"PHASE3","title":"A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Genor Biopharma Co., Ltd.","startDate":"2022-01-14","conditions":"Breast Cancer","enrollment":350},{"nctId":"NCT05337657","phase":"PHASE1","title":"A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Genor Biopharma Co., Ltd.","startDate":"2021-06-02","conditions":"Advanced Breast Cancer","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GB491 combined with Letrozole","genericName":"GB491 combined with Letrozole","companyName":"Genor Biopharma Co., Ltd.","companyId":"genor-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GB491 combined with Letrozole works by inhibiting a molecular target (likely CDK4/6 or similar cell-cycle regulator) to arrest tumor cell proliferation, while Letrozole blocks aromatase to reduce estrogen production in hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative breast cancer (presumed, based on Letrozole pairing).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}